Log in to search using one of your social media accounts:

 

Janumet (Sitagliptin Metformin HCL) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 28, 2017 Category: Drugs & Pharmacology Source Type: news

Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck ’s Supplemental New Drug Applications for JANUVIA®(sitagliptin), JANUMET® (sitagliptin and metformin HCl) and JANUMET XR® (sitagliptin and metformin HCl extended-release).Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKristen Drake, 908-236-4223orInvestors:Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NY...
Source: Merck.com - Corporate News - April 7, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news

Janumet XR (Sitagliptin and Metformin HCl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 31, 2017 Category: Drugs & Pharmacology Source Type: news

The Year In Review: Merck Can Look Back And Smile
Merck has had a reasonably good year. The company saw a turn-around in its business on the back of its relatively new cancer drug, Keytruda. The anti-infectives division sustained itself, with key metabolism drugs Januvia and Janumet gradually inching up. In fact, the competitive pressure from J&J ’s Invokana, which threatened [...] (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 13, 2016 Category: Pharmaceuticals Authors: Trefis Team, Contributor Tags: NYSE:MRK Source Type: news

EASD: Novel SGLT2 Drug Works in Triple Therapy (CME/CE)
(MedPage Today) -- Ertugliflozin improved T2D control atop metformin/sitagliptin (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - September 15, 2016 Category: Urology & Nephrology Source Type: news

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
Dateline City: KENILWORTH, N.J., and NEW YORK, N.Y.New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting – Study Achieved Primary and All Key Secondary EndpointsKENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint.Language: Englishread more (Source: Merck.com - Research and Development News)
Source: Merck.com - Research and Development News - September 15, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Five diabetes drugs in top-10 selling list; overtakes anti-infective, antibiotic meds
Insulin brand Human Mixtard, oral formulation Glycomet GP, insulin Lantus, oral formulations Galvus Met and Janumet are now in the top-selling list of drugs in the country. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 21, 2016 Category: Pharmaceuticals Source Type: news

T2D patients on combination therapy benefit in switch from sitagliptin to liraglutide
BOSTON – Switching from sitagliptin to liraglutide, in combination with metformin, improved control of hypoglycemia and resulted in greater weight loss in patients with type 2 diabetes, reported Dr.... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 10, 2016 Category: Endocrinology Source Type: news

Merck’s Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA® (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Merck’s once-daily DPP-4 inhibitor, JANUVIA® (sitagliptin), at reducing patients’ A1C* levels from baseline, with similar A1C reductions achieved in both groups. Language: ...
Source: Merck.com - Research and Development News - September 16, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

India Supreme Court Rules in Favor of Merck in Diabetes Drug Patent Suit
The Supreme Court of India has barred Mumbai-based Glenmark Pharmaceuticals from making and selling generic versions of U.S. drugmaker Merck's diabetes drugs, Januvia and Janumet. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 19, 2015 Category: Pharmaceuticals Source Type: news

Indian court bars Glenmark from selling Merck drug copies
MUMBAI (Reuters) - India's Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck's diabetes drugs Januvia and Janumet, according to a court document released on Friday. (Source: Reuters: Health)
Source: Reuters: Health - May 15, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Supreme Court bars Glenmark from selling copies of Merck diabetes drugs: Sources
Merck sued Glenmark in 2013 for infringing a patent it has on sitagliptin, the chemical compound in Januvia and Janumet. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 15, 2015 Category: Pharmaceuticals Source Type: news

Merck reports observational data of Januvia and metformin combination for type 2 Diabetes
Merck has reported data from an observational study that assessed the differences in initiated insulin therapy in patients with type 2 diabetes taking a combination of Januvia (sitagliptin) and metformin, as well as sulphonylurea and metformin. (Source: Drug Development Technology)
Source: Drug Development Technology - September 17, 2014 Category: Pharmaceuticals Source Type: news

Patients with type 2 diabetes taking JANUVIA® (sitagliptin), metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea, metformin
A late-breaking observational study has been released that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA® (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 14, 2014 Category: Science Source Type: news

Late-Breaking Observational Data Show Patients with Type 2 Diabetes Taking JANUVIA® (sitagliptin) and Metformin Initiated Insulin Therapy at a Slower Rate Compared to Patients Taking a Sulfonylurea and Metformin
In this study, patients treated with a combination of JANUVIA and metformin initiated insulin therapy at a slower rate during the period of observation than patients Language: English read more (Source: Merck.com - Research and Development News)
Source: Merck.com - Research and Development News - June 14, 2014 Category: Pharmaceuticals Tags: Research and Development News Source Type: news

Late-breaking observational data show patients with type 2 diabetes taking JANUVIA® (sitagliptin) and metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea and metformin
(GCI Health NY) Merck, known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA® (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2014 Category: Global & Universal Source Type: news

AWARD-5: Dulaglutide Betters Sitagliptin in Type 2 DiabetesAWARD-5: Dulaglutide Betters Sitagliptin in Type 2 Diabetes
In patients with type 2 diabetes uncontrolled with metformin, adding weekly injections of dulaglutide led to better glycemic control at 1 year compared with adding oral sitagliptin, with acceptable safety. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 28, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

New York Attorney Now Accepting Januvia, Janumet, Byetta or...
Commack, New York law firm, Rudolph F.X. Migliore, P.C., is accepting cases from individuals who took the prescription medication Januvia, Janumet, Byetta or Victoza and later developed pancreatic...(PRWeb November 05, 2013)Read the full story at http://www.prweb.com/releases/2013/11/prweb11297852.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 5, 2013 Category: Pharmaceuticals Source Type: news

Gliptins: IQWiG assessed data subsequently submitted by the manufacturer
(Institute for Quality and Efficiency in Health Care) New subgroup analyses showed that two studies on sitagliptin were also relevant for the fixed combination of sitagliptin/metformin. Hints of an added benefit can now be derived. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 9, 2013 Category: Global & Universal Source Type: news

Diabetes drugs may be linked to pancreatic cancer
Conclusion This article presents important concerns that glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors could potentially increase the risk of inflammation and cancerous changes in the pancreas. The agencies that regulate medicines in Europe and the USA are aware of these issues, and told the BMJ that their analyses show increased reporting of pancreatic cancer among people taking these types of drugs. However, the agencies note that it has not been established whether these drugs directly cause the adverse effects seen in the pancreas. Both agencies are reviewing eme...
Source: NHS News Feed - June 10, 2013 Category: Consumer Health News Tags: Medication Diabetes QA articles Source Type: news

Invokana Tops Januvia as Third-Line Therapy, With DrawbacksInvokana Tops Januvia as Third-Line Therapy, With Drawbacks
In patients with type 2 diabetes not controlled with metformin plus sulfonylurea, adding canagliflozin provided better glucose control than adding sitagliptin, but with increased genital infections. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 16, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Sitagliptin and exenatide associated with an increased risk of acute pancreatitis
Source: JAMA Internal Medicine Area: News According to a study published in JAMA Internal Medicine, treatment of type 2 diabetes mellitus with the glucagon-like peptide (GLP)-1-based therapies sitagliptin and exenatide was associated with increased odds of hospitalisation for acute pancreatitis.   A large administrative database in the United States  was used to collect data for the  population-based case-control study - adults with type 2 diabetes mellitus aged 18 to 64 years were identified and 1269 hospitalised cases with acute pancreatitis using a validated algorithm and 1269 control subjects matche...
Source: NeLM - News - February 26, 2013 Category: Drugs & Pharmacology Source Type: news

Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results
Dateline City:  WHITEHOUSE STATION, N.J. 2012 Full-Year Non-GAAP EPS of $3.82, Excluding Certain Items; GAAP EPS of $2.16; Fourth-Quarter Non-GAAP EPS of $0.83, Excluding Certain Items; GAAP EPS of $0.46 2012 Full-Year Worldwide Sales Were $47.3 Billion, a Decrease of 2 Percent, Including a 3 Percent Unfavorable Impact from Foreign Exchange; Fourth-Quarter Worldwide Sales Were $11.7 Billion, a Decline of 5 Percent, Including a 2 Percent Unfavorable Impact from Foreign Exchange Full-Year and Fourth-Quarter Double-Digit Gl...
Source: Merck.com - Corporate News - February 1, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Source Type: news